The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Rechallenge with anti-EGFR–based therapy in metastatic colorectal cancer: Impact of intervening time interval and prior anti-EGFR response.
Xiaochun Liu
No relevant relationships to disclose
Goldy C. George
No relevant relationships to disclose
Apostolia Maria Tsimberidou
No relevant relationships to disclose
Aung Naing
No relevant relationships to disclose
Jennifer J. Wheler
No relevant relationships to disclose
Scott Kopetz
No relevant relationships to disclose
Siqing Fu
No relevant relationships to disclose
Sarina Anne Piha-Paul
No relevant relationships to disclose
Cathy Eng
No relevant relationships to disclose
Gerald Steven Falchook
No relevant relationships to disclose
Filip Janku
No relevant relationships to disclose
Chris R. Garrett
No relevant relationships to disclose
Daniel D. Karp
No relevant relationships to disclose
Razelle Kurzrock
No relevant relationships to disclose
Ralph Zinner
No relevant relationships to disclose
Kanwal Pratap Singh Raghav
No relevant relationships to disclose
Vivek Subbiah
No relevant relationships to disclose
Funda Meric-Bernstam
No relevant relationships to disclose
David S. Hong
No relevant relationships to disclose
Michael J. Overman
Research Funding - Amgen; Bristol-Myers Squibb